Fig. 1: Outcomes after UCBT or PBSCT in patients with hematopoietic malignancies. | Nature Communications

Fig. 1: Outcomes after UCBT or PBSCT in patients with hematopoietic malignancies.

From: Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients

Fig. 1

a Number of HSCT procedures performed per year. b The cumulative incidence of pre-engraftment syndrome in patients after UCBT or PBSCT. c–f The cumulative incidence of grades III–IV acute graft-versus-host disease at day 100, 3-year nonrelapse mortality, 3-year overall survival, and 3-year disease-free survival of patients with different PES grades: III–IV aGVHD (c), nonrelapse mortality (d), overall survival (e), and leukemia-free survival (f). The probabilities of PES, III–IV aGVHD and nonrelapse mortality as summarized by the cumulative incidence of competing events. The probabilities of overall survival and disease-free survival were calculated with Kaplan–Meier curves. Source data are provided as a Source Data file.

Back to article page